Search company, investor...


Founded Year




Total Raised


Market Cap


Stock Price


About Vermillion

Vermillion, formerly Ciphergen Biosystems, is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health. Vermillion is based in Fremont, California.

Headquarters Location

47350 Fremont Boulevard

Fremont, California, 94538,

United States


Missing: Vermillion's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Vermillion's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Vermillion

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Vermillion is included in 3 Expert Collections, including Women's Health & Wellness.


Women's Health & Wellness

1,493 items

Startups focused on providing products and services catering to women's health and wellbeing.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Vermillion Patents

Vermillion has filed 35 patents.

The 3 most popular patent topics include:

  • Beer vessels and serving
  • Cancer treatments
  • Container deposit legislation
patents chart

Application Date

Grant Date


Related Topics




Clusters of differentiation, Proteins, Oncology, Transcription factors, Tumor markers


Application Date


Grant Date



Related Topics

Clusters of differentiation, Proteins, Oncology, Transcription factors, Tumor markers



Latest Vermillion News

Vermillion Completes Validation Of New Pre-Surgical Test Offerings With OVA1®plus, Including COVID-19 Antibody Testing And Additional Pelvic Mass Risk Assessment Biomarkers

Jun 10, 2020

Vermillion Completes Validation Of New Pre-Surgical Test Offerings With OVA1®plus, Including COVID-19 Antibody Testing And Additional Pelvic Mass Risk Assessment Biomarkers AUSTIN, Texas, June 10, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women's health company focused on gynecologic disease, is excited to announce that its wholly-owned subsidiary ASPIRA Labs has completed laboratory... Author: Jun 10, 2020 8:00 AM EDT AUSTIN, Texas, June 10, 2020 (GLOBE NEWSWIRE) -- Vermillion, Inc. (Nasdaq: VRML), a bioanalytical-based women's health company focused on gynecologic disease, is excited to announce that its wholly-owned subsidiary ASPIRA Labs has completed laboratory validation of the Roche Elecsys Anti-SARS-CoV-2 antibody test for detecting the presence of COVID-19 antibodies. Our Laboratory has also completed validation of several additional oncology biomarkers. Both the COVID-19 antibody test and additional biomarkers will be used in an ASPIRA pelvic mass risk assessment pre-surgery workup. ASPIRA Labs selected to validate the Roche Elecsys Anti-SARS-CoV-2 antibody test because it detects both IgG and IgM antibodies. Testing for IgG and IgM antibodies yields a specificity of 99.81% and a sensitivity of 100% (100% sensitivity when ≥14 days post PCR confirmation) 1. The completed validation of COVID-19 antibody and additional pelvic mass risk assessment biomarkers will be offered commercially by the end of June in conjunction with our proprietary OVA1 ®plus test. The additional oncology biomarkers are CEA, CA19.9, LDH, Beta HCG, and AFP. These laboratory tests are essential in helping physicians identify less frequent ovarian tumor types as part of the pre-surgical workup. "These additional offerings further establish ASPIRA Labs as a leader in pelvic mass assessment by providing physicians the ability to order tests for additional biomarkers. These offerings also help ensure physicians get access to all the testing they need to assess pelvic mass ovarian cancer risk especially in the current healthcare environment with COVID-19," said Valerie Palmieri, President and Chief Executive Officer of Vermillion, Inc. About Vermillion Inc.Vermillion, Inc. is transforming women's health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management and improve gynecologic health outcomes for women. OVA1 ®plus combines our FDA-cleared products OVA1 ® and OVERA ® to detect the risk of ovarian malignancy in women with adnexal masses. Recently launched, ASPiRA GenetiX SM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Vermillion has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment plans. Visit our website for more information about our products at . 1. Roche Diagnostics Product Release Bulletin "Elecsys ® Anti-SARS-CoV-2 Immunoassay" Forward-Looking StatementsThis press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995 including statements regarding the anticipated addition of Vermillion common stock to the Russell 3000 Index and effects thereof. These statements involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements. Words such as "may," "expects," "intends," "anticipates," "believes," "estimates," "plans," "seeks," "could," "should," "continue," "will," "potential," "projects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties inherent in Vermillion's business, including those described in the section entitled "Risk Factors" in Vermillion's Annual Report on Form 10-K for the year ended December 31, 2019, as supplemented by the section entitled "Risk Factors" in Vermillion's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020. The events and circumstances reflected in Vermillion's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law. Investor Relations Contact: Ashley R. RobinsonLifeSci Advisors, LLCTel 617-430-7577 By

Vermillion Frequently Asked Questions (FAQ)

  • When was Vermillion founded?

    Vermillion was founded in 1993.

  • Where is Vermillion's headquarters?

    Vermillion's headquarters is located at 47350 Fremont Boulevard, Fremont.

  • What is Vermillion's latest funding round?

    Vermillion's latest funding round is PIPE - II.

  • How much did Vermillion raise?

    Vermillion raised a total of $53.35M.

  • Who are the investors of Vermillion?

    Investors of Vermillion include Cancer Prevention and Research Institute of Texas, Falcon Technology Venture Partners, Quest Diagnostics, Northern Trust, Iroquois Capital Group and 28 more.

  • Who are Vermillion's competitors?

    Competitors of Vermillion include ChemoCentryx, Oligomerix, LeadScope, NGM Biopharmaceuticals, Dyax and 10 more.

Compare Vermillion to Competitors


ARCXIS develops, produces, and distributes portable biological diagnostic tools with the ability to analyze, detect, and characterize infectious disease agents. It develops diagnostic tools for use in national defense, clinical diagnostics, as well as food and beverage applications. The company was founded in 2004 and is based in Houston, Texas.

Oligomerix Logo

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.

Proteome Systems

Tyrian Diagnostics is a biotechnology company that specialises in the discovery of biomarkers of disease and in diagnostic test development. The company are building a strong intellectual property portfolio to develop a pipeline of diagnostic products and establishing commercial partnerships to maximise market share and revenue generation from these products. One key avenue for commercialisation is the application of biomarkers to the company's point of need test platform, DiagnostIQTM.


RevDia is a provider of a therapeutic diagnostic testing platform. The company's diagnostic testing platform is designed to detect an active periodontal infection. Its technology is intended to measure elevated levels of slgA in saliva that is specific to Aa and Pg virulence proteins, an attribute displayed by bacteria when it becomes pathogenic during an active infection.


Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

Aliva Biopharmaceuticals

Aliva Biopharmaceuticals is a company that received a SBIR Phase I grant for a project entitled: Humanized Mouse Ig system employing BAC. Their research project aims to introduce the entire human immunoglobulin locus into the mouse in order to enable the subsequent production of completely humanized monoclonal antibodies from hybridomas. Monoclonal antibodies against cell surface proteins are currently being used for a variety of clinical indications, including cancer and autoimmunity. Their binding avidity and specificity make them one of the most important modes of therapy for the treatment of a variety of diseases where specific targeting is required. The current technology is based on a system where only 80% of the immunoglobulin locus has been humanized. Replacement of the remaining mouse genes with the human ones will improve the quality and diversity of the antibodies produced and as such, will be an important contribution to this important therapeutic modality.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.